BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li A, Bhatraju PK, Chen J, Chung DW, Hilton T, Houck K, Pao E, Weiss NS, Lee SJ, Davis C, Schmidt MJ, Lopez JA, Liles WC, Dong JF, Hingorani SR. Prognostic Biomarkers for Thrombotic Microangiopathy after Acute Graft-versus-Host Disease: A Nested Case-Control Study. Transplant Cell Ther 2021;27:308.e1-8. [PMID: 33836868 DOI: 10.1016/j.jtct.2020.12.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Higham CS, Shimano KA, Melton A, Kharbanda S, Chu J, Dara J, Winestone LE, Hermiston ML, Huang JN, Dvorak CC. A pilot trial of prophylactic defibrotide to prevent serious thrombotic microangiopathy in high-risk pediatric patients. Pediatr Blood Cancer 2022;69:e29641. [PMID: 35253361 DOI: 10.1002/pbc.29641] [Reference Citation Analysis]
2 Okamura H, Nakamae H, Shindo T, Ohtani K, Hidaka Y, Ohtsuka Y, Makuuchi Y, Kuno M, Takakuwa T, Harada N, Nishimoto M, Nakashima Y, Koh H, Hirose A, Nakamae M, Wakamiya N, Hino M, Inoue N. Early Elevation of Complement Factor Ba Is a Predictive Biomarker for Transplant-Associated Thrombotic Microangiopathy. Front Immunol 2021;12:695037. [PMID: 34326846 DOI: 10.3389/fimmu.2021.695037] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
3 Li A, Gupta R, Amos CI, Davis C, Pao E, Lee SJ, Hingorani SR. Thrombotic microangiopathy increases the risk of chronic kidney disease but not overall mortality in long-term transplant survivors. Transplant Cell Ther 2021:S2666-6367(21)01030-7. [PMID: 34217847 DOI: 10.1016/j.jtct.2021.06.027] [Reference Citation Analysis]